Cargando…
circSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer by Targeting the miR-520h/ABCG2 Pathway
Gefitinib is a first-line treatment for patients with non-small-cell lung cancer (NSCLC), but acquired resistance is a major obstacle to its therapeutic efficacy, and the underlying mechanisms are not fully elucidated. Recent studies have indicated that circular RNAs play a crucial role in chemoresi...
Autores principales: | Huang, Yutang, Dai, Yi, Wen, Chunjie, He, Shuai, Shi, Jingjing, Zhao, Dezhang, Wu, Lanxiang, Zhou, Honghao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452060/ https://www.ncbi.nlm.nih.gov/pubmed/32805491 http://dx.doi.org/10.1016/j.omtn.2020.07.027 |
Ejemplares similares
-
ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
por: Zhao, Hongbo, et al.
Publicado: (2018) -
Screening Circular RNAs Related to Acquired Gefitinib Resistance in Non-small Cell Lung Cancer Cell Lines
por: Wen, Chunjie, et al.
Publicado: (2020) -
CircSETD2 inhibits YAP1 by interaction with HuR during breast cancer progression
por: Jing, Lan, et al.
Publicado: (2023) -
Hypoxia-induced miR-653 enhances colorectal cancer progression by targeting circSETD3/KLF6 axis
por: Chen, Qian, et al.
Publicado: (2023) -
CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth
por: Xu, Liangliang, et al.
Publicado: (2019)